Edwards Lifesciences Corporation

NYSE:EW Stock Report

Market Cap: US$48.9b

Edwards Lifesciences Valuation

Is EW undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of EW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Fair Value: EW ($84.35) is trading below our estimate of fair value ($86.14)

Significantly Below Fair Value: EW is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EW?

Key metric: As EW is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EW. This is calculated by dividing EW's market cap by their current earnings.
What is EW's PE Ratio?
PE Ratio36.5x
EarningsUS$1.34b
Market CapUS$48.95b

Price to Earnings Ratio vs Peers

How does EW's PE Ratio compare to its peers?

The above table shows the PE ratio for EW vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average33.4x
BDX Becton Dickinson
35.2x14.16%US$59.0b
IDXX IDEXX Laboratories
55.6x9.96%US$57.1b
GEHC GE HealthCare Technologies
16.8x5.90%US$37.2b
RMD ResMed
26.1x8.91%US$37.5b
EW Edwards Lifesciences
36.5x11.72%US$48.9b

Price-To-Earnings vs Peers: EW is expensive based on its Price-To-Earnings Ratio (36.5x) compared to the peer average (33.4x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does EW's PE Ratio compare vs other companies in the US Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA.F Meihua International Medical Technologies
0.2xn/aUS$2.26m
ARTH.Q Arch Therapeutics
n/an/aUS$4.00
No more companies available in this PE range
EW 36.5xIndustry Avg. 31.2xNo. of Companies10PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EW is expensive based on its Price-To-Earnings Ratio (36.5x) compared to the US Medical Equipment industry average (31.2x).

Price to Earnings Ratio vs Fair Ratio

What is EW's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EW PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio36.5x
Fair PE Ratio31.8x

Price-To-Earnings vs Fair Ratio: EW is expensive based on its Price-To-Earnings Ratio (36.5x) compared to the estimated Fair Price-To-Earnings Ratio (31.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EW forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$84.35
US$96.69
+14.63%
6.69%US$108.00US$84.00n/a28
Jan ’27US$85.25
US$95.80
+12.38%
6.63%US$105.00US$84.00n/a28
Dec ’26US$85.27
US$93.94
+10.17%
6.67%US$105.00US$83.00n/a28
Nov ’26US$82.45
US$93.31
+13.17%
6.99%US$105.00US$83.00n/a27
Oct ’26US$76.31
US$87.16
+14.22%
7.20%US$100.00US$72.00n/a30
Sep ’26US$81.34
US$87.55
+7.64%
7.85%US$101.00US$72.00n/a30
Aug ’26US$79.33
US$87.32
+10.07%
8.00%US$101.00US$72.00n/a30
Jul ’26US$77.18
US$81.01
+4.96%
8.43%US$95.00US$61.00n/a29
Jun ’26US$78.22
US$80.97
+3.51%
8.46%US$95.00US$61.00n/a30
May ’26US$75.18
US$80.30
+6.81%
7.92%US$90.00US$61.00n/a30
Apr ’26US$71.87
US$80.14
+11.51%
9.11%US$96.80US$61.00n/a30
Mar ’26US$71.62
US$80.42
+12.29%
9.37%US$96.80US$61.00n/a30
Feb ’26US$72.45
US$79.49
+9.72%
10.22%US$96.80US$60.00n/a30
Jan ’26US$74.03
US$79.30
+7.12%
9.54%US$96.80US$68.00US$85.2529
Dec ’25US$71.35
US$76.61
+7.37%
9.76%US$96.80US$63.00US$85.2728
Nov ’25US$67.54
US$76.36
+13.05%
9.76%US$96.80US$63.00US$82.4528
Oct ’25US$65.10
US$77.66
+19.30%
9.58%US$96.80US$65.00US$76.3127
Sep ’25US$69.96
US$81.45
+16.43%
11.08%US$101.43US$65.00US$81.3427
Aug ’25US$61.86
US$81.45
+31.67%
11.08%US$101.43US$65.00US$79.3327
Jul ’25US$90.25
US$96.05
+6.43%
10.22%US$107.00US$70.00US$77.1827
Jun ’25US$86.89
US$96.55
+11.12%
9.65%US$107.00US$73.00US$78.2228
May ’25US$84.30
US$95.38
+13.14%
9.46%US$105.00US$73.00US$75.1828
Apr ’25US$94.25
US$92.61
-1.74%
9.19%US$105.00US$72.00US$71.8728
Mar ’25US$85.22
US$91.29
+7.12%
8.33%US$105.00US$72.00US$71.6228
Feb ’25US$78.71
US$80.04
+1.69%
12.32%US$96.00US$57.00US$72.4528
Jan ’25US$76.25
US$79.61
+4.41%
12.31%US$96.00US$57.00US$74.0328
US$96.69
Fair Value
12.8% undervalued intrinsic discount
28
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/18 00:19
End of Day Share Price 2026/01/16 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Edwards Lifesciences Corporation is covered by 57 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RescottBaird
Adam FeinsteinBarclays
Matthew MiksicBarclays